Announcements Trials
Browse Landscape

Phase

Phase 3 1Phase 1 1

Status

Completed 1Active not recruiting 1

Sponsor Class

OTHER 1INDUSTRY 1

Study Type

Interventional 2

Sponsor

Cancer Type

Breast 2

Conditions

Breast Neoplasms 91Neoplasm Metastasis 24Neoplasms 14Brain Neoplasms 13Prostatic Neoplasms 10Endometrial Neoplasms 10Carcinoma, Non-Small-Cell Lung 10Ovarian Neoplasms 7Glioblastoma 7Glioma 6Triple Negative Breast Neoplasms 5Squamous Cell Carcinoma of Head and Neck 5Head and Neck Neoplasms 5Colorectal Neoplasms 5Sarcoma 4Recurrence 4Pancreatic Neoplasms 4Lymphoma, Non-Hodgkin 4Sarcoma, Ewing 3Osteosarcoma 3Neoplasms by Site 3Multiple Myeloma 3Meningioma 3Melanoma 3Carcinoma, Renal Cell 3Breast Diseases 3Unilateral Breast Neoplasms 2Rhabdomyosarcoma 2Rhabdoid Tumor 2Oligodendroglioma 2

Interventions

abemaciclib 2Radiotherapy 2sargramostim 1ribociclib 1palbociclib 1niraparib 1exemestane 1Mastectomy, Segmental 1Mastectomy 1Letrozole 1Fulvestrant 1Everolimus 1Cyclophosphamide 1Continuous Positive Airway Pressure 1Colony-Stimulating Factors 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Interventional × Unilateral Breast Neoplasms × abemaciclib × Clear all
NCT06760637 2026-05-19

FourLight-3

Pfizer

Phase 3 Active not recruiting
1,035 enrolled
Breast

Unilateral Breast Neoplasms, Breast Neoplasms, Recurrence

NCT04481113 2026-01-29

Abemaciclib and Niraparib Before Surgery for the Treatment of Hormone Receptor Positive HER2 Negative Breast Cancer

OHSU Knight Cancer Institute

Phase 1 Completed
8 enrolled
Breast

Unilateral Breast Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡